SCHEMBL1778067

SCHEMBL1778067

N#Cc1ccc(OCCCCCCl)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.58
HDAC1 Q13547 1/20 0.53
HDAC2 Q92769 1/20 0.53
ALDH1A1 P00352 3/20 0.50
MAPT P10636 2/20 0.50
MMP3 P08254 2/20 0.50
KDM4E B2RXH2 2/20 0.49
HPGD P15428 2/20 0.49
HTT P42858 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HRH2 P25021 4/20 0.49
HRH1 P35367 4/20 0.49
MMP2 P08253 2/20 0.49
MAOB P27338 1/20 0.47
ALDH3A1 P30838 1/20 0.46
MMP1 P03956 1/20 0.45
MMP9 P14780 1/20 0.45
MMP13 P45452 1/20 0.45
TBXAS1 P24557 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6731770 1.00 HRH3 (0.58) HRH3HDAC1HDAC2ALDH1A1MAPT
SCHEMBL8748087 0.98 HRH3 (0.56) HRH3HDAC1HDAC2ALDH1A1MAPT
SCHEMBL6709103 0.92 MMP3 (0.59) HRH3HDAC1HDAC2ALDH1A1MMP3
SCHEMBL1714609 0.92 HRH3 (0.54) HRH3HDAC1HDAC2ALDH1A1MAPT
SCHEMBL12408526 0.92 HRH3 (0.66) HRH3HDAC1HDAC2ALDH1A1MAPT
SCHEMBL5526919 0.92 HRH3 (0.66) HRH3HDAC1HDAC2ALDH1A1MAPT
SCHEMBL7387284 0.92 HRH3 (0.66) HRH3HDAC1HDAC2ALDH1A1MAPT
SCHEMBL7983991 0.92 HRH3 (0.66) HRH3HDAC1HDAC2ALDH1A1MAPT
SCHEMBL5519875 0.89 HRH3 (0.62) HRH3HDAC1HDAC2ALDH1A1MAPT
SCHEMBL7447851 0.88 ALDH1A1 (0.53) HRH3ALDH1A1MAPTMMP3HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1980905-B An improved process for preparing n-hydroxy-4-{5- [4- (5-isopropyl-2-methyl-l, 3-thiazol-4-yl) -phenoxy] -pentoxy }-benzamidine DONG WHA PHARM IND CO LTD 2010-04-21 CN claimed
EP-1773794-A4 AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-[5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY]-BENZAMIDINE DONG WHA PHARM IND CO LTD (KR) 2009-09-09 EP claimed
US-7585979-B2 Process for preparing N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy]-pentoxy}-benzamidine DONG WHA PHARMACEUTICAL IND. CO., LTD. (KR) 2009-09-08 US claimed
US-20080125596-A1 Process For Preparing N-Hydroxy-4--Benzamidine DONG WHA PHARMACEUTICAL CO., LTD. (KR) 2008-05-29 US claimed
CN-1980905-A An improved process for preparing n-hydroxy-4-{5- [4- (5-isopropyl-2-methyl-l, 3-thiazol-4-yl) -phenoxy] -pentoxy }-benzamidine DONG WHA PHARM IND CO LTD (KR) 2007-06-13 CN claimed
EP-1773794-A1 AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-[5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY]-BENZAMIDINE DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) 2007-04-18 EP claimed
WO-2006004368-A1 AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-{5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY }-BENZAMIDINE DONG WHA PHARMACEUTICAL. IND. CO., LTD. (KR) 2006-01-12 WO claimed
EP-1781629-B1 NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DONG WHA PHARM CO LTD (KR) 2015-07-29 EP disclosed
US-8178688-B2 Benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same DONG WHA PHARMACEUTICAL CO., LTD. (KR) 2012-05-15 US disclosed
CN-101379049-B Novel benzamidine derivatives, process for preparing the same, and pharmaceutical composition comprising the same DONG WHA PHARM IND CO LTD 2012-01-04 CN disclosed
EP-1979334-B1 NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DONG WHA PHARM CO LTD (KR) 2011-06-22 EP disclosed
US-7943646-B2 Benzamidine derivative, process for the preparation thereof and pharmaceutical composition comprising same DONG WHA PHARMACEUTICAL CO., LTD. (KR) 2011-05-17 US disclosed
US-20100249402-A1 NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEPOROSIS COMPRISING THE SAME DONG WHA PHARMACEUTICAL CO. LTD. (KR) 2010-09-30 US disclosed
WO-2006014087-A1 NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DONG WHA PHARMACEUTICAL. IND. CO., LTD. (KR) 2006-02-09 WO disclosed
WO-2006004368-A1 AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-{5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY }-BENZAMIDINE DONG WHA PHARMACEUTICAL. IND. CO., LTD. (KR) 2006-01-12 WO disclosed
EP-0601977-B1 Aromatic hydroxyamidine derivatives and their use as leukotriene B4 receptor antagonists CIBA GEIGY AG (CH) 1997-01-22 EP disclosed
US-5455274-A Leukotriene antagonists; treating rheumatoid arthritis CIBA-GEIGY CORPORATION (US) 1995-10-03 US disclosed
EP-0601977-A1 Aromatic hydroxyamidine derivatives and their use as leukotriene B4 receptor anagonists CIBA-GEIGY AG (CH) 1994-06-15 EP disclosed
US-5246965-A Leukotriene antagonist CIBA-GEIGY (US) 1993-09-21 US disclosed
EP-0518818-A2 Arylethers, their manufacture and use as medicament CIBA-GEIGY AG (CH) 1992-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249402-A1 NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEPOROSIS COMPRISING THE SAME SOST, CTSA, BECN1 HRH3 167/4885HDAC1 1363/4885HDAC2 353/4885
US-20080125596-A1 Process For Preparing N-Hydroxy-4--Benzamidine HNMT, HTR4, PNMT HRH3 15/4885HDAC1 2806/4885HDAC2 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.